RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to determine the effectiveness of monoclonal antibody in treating patients with recurrent gliomas.
OBJECTIVES: I. Assess the toxic effects of intracystic administration of iodine-131-labeled anti-tenascin monoclonal antibody 81C6. II. Identify any objective therapeutic responses to this treatment in patients with recurrent cystic anaplastic gliomas. OUTLINE: Radioimmunotherapy. Iodine-131-Labeled Anti-Tenascin Monoclonal Antibody 81C6, 131I-81C6. PROJECTED ACCRUAL: Three to six patients will be entered at each dose studied.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
6
Duke Comprehensive Cancer Center
Durham, North Carolina, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.